 Gwendolyn Kerby
Concepts (134)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tobacco Smoke Pollution | 7 | 2023 | 217 | 1.000 |
Why?
| | Cystic Fibrosis | 9 | 2018 | 956 | 0.870 |
Why?
| | Respiratory Function Tests | 8 | 2015 | 524 | 0.800 |
Why?
| | Smoking Cessation | 4 | 2022 | 374 | 0.550 |
Why?
| | Pseudomonas Infections | 2 | 2018 | 185 | 0.490 |
Why?
| | Spirometry | 4 | 2012 | 225 | 0.460 |
Why?
| | Cough | 3 | 2013 | 107 | 0.420 |
Why?
| | Neuroendocrine Cells | 1 | 2012 | 30 | 0.410 |
Why?
| | Lung | 4 | 2015 | 3593 | 0.320 |
Why?
| | Plethysmography | 4 | 2012 | 104 | 0.310 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 515 | 0.290 |
Why?
| | Cotinine | 3 | 2021 | 69 | 0.260 |
Why?
| | Child, Preschool | 12 | 2022 | 9086 | 0.240 |
Why?
| | Prednisone | 2 | 2019 | 231 | 0.230 |
Why?
| | Sodium Chloride | 2 | 2015 | 136 | 0.220 |
Why?
| | Dexamethasone | 2 | 2019 | 317 | 0.210 |
Why?
| | Motivational Interviewing | 1 | 2023 | 87 | 0.200 |
Why?
| | Forced Expiratory Volume | 4 | 2015 | 476 | 0.200 |
Why?
| | Pediatricians | 1 | 2023 | 122 | 0.200 |
Why?
| | Child, Hospitalized | 2 | 2020 | 38 | 0.200 |
Why?
| | Electronic Health Records | 2 | 2021 | 802 | 0.200 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2002 | 144 | 0.200 |
Why?
| | Oscillometry | 2 | 2011 | 33 | 0.190 |
Why?
| | Hospitals, Pediatric | 3 | 2019 | 479 | 0.190 |
Why?
| | Respiratory Physiological Phenomena | 1 | 2021 | 29 | 0.180 |
Why?
| | Information Systems | 1 | 2021 | 61 | 0.180 |
Why?
| | Sample Size | 1 | 2010 | 114 | 0.180 |
Why?
| | Infant | 11 | 2022 | 7937 | 0.170 |
Why?
| | Parents | 4 | 2021 | 1191 | 0.170 |
Why?
| | Azithromycin | 1 | 2018 | 80 | 0.150 |
Why?
| | Clinical Trials as Topic | 2 | 2011 | 934 | 0.140 |
Why?
| | Macrophages | 1 | 2002 | 1266 | 0.130 |
Why?
| | Child | 11 | 2023 | 18366 | 0.120 |
Why?
| | Environmental Exposure | 1 | 2018 | 377 | 0.120 |
Why?
| | Bronchoscopy | 1 | 2016 | 246 | 0.120 |
Why?
| | Pseudomonas aeruginosa | 2 | 2018 | 299 | 0.120 |
Why?
| | Male | 15 | 2023 | 55663 | 0.110 |
Why?
| | Humans | 20 | 2023 | 114937 | 0.100 |
Why?
| | Hyperplasia | 1 | 2012 | 164 | 0.100 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 53 | 0.100 |
Why?
| | Cross-Sectional Studies | 2 | 2012 | 4407 | 0.100 |
Why?
| | Asthma | 2 | 2019 | 2042 | 0.100 |
Why?
| | Feasibility Studies | 2 | 2011 | 737 | 0.100 |
Why?
| | Anti-Bacterial Agents | 2 | 2018 | 1477 | 0.100 |
Why?
| | Longitudinal Studies | 3 | 2013 | 2382 | 0.090 |
Why?
| | Colorado | 3 | 2020 | 4091 | 0.090 |
Why?
| | Practice Patterns, Physicians' | 1 | 2019 | 1177 | 0.090 |
Why?
| | Female | 13 | 2023 | 59581 | 0.090 |
Why?
| | Patient Readmission | 1 | 2016 | 608 | 0.090 |
Why?
| | Reproducibility of Results | 3 | 2013 | 2770 | 0.090 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 1700 | 0.090 |
Why?
| | Smoking Prevention | 2 | 2021 | 157 | 0.090 |
Why?
| | Smoking | 3 | 2021 | 1391 | 0.080 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2011 | 287 | 0.080 |
Why?
| | Inpatients | 2 | 2022 | 380 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2012 | 4427 | 0.070 |
Why?
| | Caregivers | 2 | 2023 | 714 | 0.070 |
Why?
| | Postoperative Complications | 1 | 2016 | 2133 | 0.060 |
Why?
| | Double-Blind Method | 3 | 2018 | 1663 | 0.060 |
Why?
| | Case-Control Studies | 1 | 2011 | 3008 | 0.060 |
Why?
| | Administration, Inhalation | 2 | 2018 | 642 | 0.060 |
Why?
| | Glucocorticoids | 1 | 2008 | 534 | 0.060 |
Why?
| | Adolescent | 5 | 2022 | 17829 | 0.060 |
Why?
| | MAP Kinase Kinase 4 | 1 | 2002 | 23 | 0.050 |
Why?
| | Chromones | 1 | 2002 | 35 | 0.050 |
Why?
| | Osmotic Pressure | 1 | 2002 | 28 | 0.050 |
Why?
| | Flavonoids | 1 | 2002 | 67 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2002 | 113 | 0.050 |
Why?
| | Mice, Inbred C3H | 1 | 2002 | 242 | 0.050 |
Why?
| | Cohort Studies | 1 | 2011 | 4903 | 0.050 |
Why?
| | Morpholines | 1 | 2002 | 102 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 164 | 0.050 |
Why?
| | Recurrence | 2 | 2018 | 937 | 0.050 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2002 | 262 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2021 | 258 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2002 | 278 | 0.050 |
Why?
| | Counseling | 1 | 2023 | 342 | 0.050 |
Why?
| | MAP Kinase Signaling System | 1 | 2002 | 276 | 0.040 |
Why?
| | Tobacco Use | 1 | 2020 | 60 | 0.040 |
Why?
| | Retrospective Studies | 2 | 2016 | 12544 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2002 | 400 | 0.040 |
Why?
| | Vital Capacity | 1 | 2010 | 257 | 0.040 |
Why?
| | Tobacco Products | 1 | 2020 | 101 | 0.040 |
Why?
| | Pulmonologists | 1 | 2019 | 16 | 0.040 |
Why?
| | Symptom Flare Up | 1 | 2019 | 38 | 0.040 |
Why?
| | Drug Substitution | 1 | 2019 | 46 | 0.040 |
Why?
| | Cell Survival | 1 | 2002 | 1022 | 0.040 |
Why?
| | Enzyme Inhibitors | 1 | 2002 | 752 | 0.040 |
Why?
| | Reference Values | 1 | 2010 | 741 | 0.040 |
Why?
| | Proto-Oncogene Proteins | 1 | 2002 | 611 | 0.040 |
Why?
| | Tobramycin | 1 | 2018 | 47 | 0.040 |
Why?
| | Directive Counseling | 1 | 2018 | 41 | 0.040 |
Why?
| | Family | 1 | 2022 | 590 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2002 | 1134 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2019 | 718 | 0.040 |
Why?
| | Pneumonia | 1 | 2002 | 568 | 0.030 |
Why?
| | Consensus | 1 | 2019 | 534 | 0.030 |
Why?
| | Hospitalists | 1 | 2019 | 174 | 0.030 |
Why?
| | Dimensional Measurement Accuracy | 1 | 2015 | 12 | 0.030 |
Why?
| | Pediatrics | 1 | 2023 | 984 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2018 | 9105 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 954 | 0.030 |
Why?
| | Self Report | 1 | 2019 | 696 | 0.030 |
Why?
| | Social Support | 1 | 2018 | 528 | 0.030 |
Why?
| | Prospective Studies | 3 | 2012 | 6218 | 0.030 |
Why?
| | Cells, Cultured | 1 | 2002 | 3897 | 0.030 |
Why?
| | Adult | 3 | 2020 | 30608 | 0.030 |
Why?
| | Young Adult | 2 | 2020 | 10478 | 0.030 |
Why?
| | Emergency Service, Hospital | 2 | 2019 | 1813 | 0.030 |
Why?
| | Functional Residual Capacity | 1 | 2013 | 7 | 0.030 |
Why?
| | Apoptosis | 1 | 2002 | 2371 | 0.030 |
Why?
| | Clinical Competence | 1 | 2019 | 901 | 0.030 |
Why?
| | Isotonic Solutions | 1 | 2012 | 38 | 0.030 |
Why?
| | Radiography, Thoracic | 1 | 2013 | 162 | 0.030 |
Why?
| | Age Factors | 1 | 2019 | 2891 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2019 | 2542 | 0.020 |
Why?
| | United States | 2 | 2021 | 12211 | 0.020 |
Why?
| | Infant, Newborn | 1 | 2022 | 5035 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 180 | 0.020 |
Why?
| | Hospitalization | 1 | 2019 | 1754 | 0.020 |
Why?
| | Staphylococcus aureus | 1 | 2013 | 385 | 0.020 |
Why?
| | Middle Aged | 2 | 2018 | 26806 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2010 | 6364 | 0.020 |
Why?
| | Staphylococcal Infections | 1 | 2013 | 336 | 0.020 |
Why?
| | Quality Improvement | 1 | 2016 | 954 | 0.020 |
Why?
| | Time Factors | 1 | 2018 | 6125 | 0.020 |
Why?
| | Body Weight | 1 | 2012 | 868 | 0.020 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 387 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2008 | 495 | 0.020 |
Why?
| | Mice | 1 | 2002 | 14936 | 0.020 |
Why?
| | Administration, Oral | 1 | 2008 | 731 | 0.020 |
Why?
| | Risk Factors | 1 | 2016 | 8637 | 0.010 |
Why?
| | Aged | 1 | 2010 | 19122 | 0.010 |
Why?
| | Animals | 1 | 2002 | 31839 | 0.010 |
Why?
|
|
Kerby's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|